PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

THE EVALUATION OF CONCENTRATION OF PROSTATE SPECIFIC ANTIGEN (PSA) IN THE PLASMA OF PATIENTS WITH PROSTATE CARCINOMA
Article published in Urologia Polska 1989/42/1.

authors

Jan Kulpa, Antonina Marczyńska, Ewa Wójcik, Andrzej Bugajski, Jan Leńko
Z Zakładu Analityki i Biochemii Klinicznej Centrum Onkologii
Instytutu im. M. Skłodowskiej-Curie Oddział w Krakowie
Kierownik Zakładu: prof. zw. dr hab. med. A. Marczyńska
Dyrektor Centrum Oddział w Krakowie: prof. dr hab. med. J. Skołyszewski
Z Kliniki Urologii Akademii Medycznej im. M. Kopernika w Krakowie
Kierownik Kliniki: prof. zw. dr med. J. Leńko

summary

Measurements of PSA concentration in the plasma were made before therapy in 84 patients with prostate carcinoma in various stages of clinical progression, in 97 patients with prostatic adenoma and in a Control group of 33 healthy males. It was found that in patients with prostatic carcinoma the PSA concentration is significantly higher than in healthy males or patients with prostatic adenoma (ex-cluding stage A). The proportions of higher concentrations in patients with prostate carcinoma reveal a clear rising tendency as the disease progresses. The evaluation of PSA concentration in the plasma of patients with prostatic carcinoma may be useful information in diagnozing such patients, particularly in estimating a stage of progression.

references

  1. 1. Althoff E.P., Proppe K.H., Chapman C.M., Lee Ch, Prof G.R.: Evaluation
  2. of prostate specific acid phosphatase and prostate specific antigen in identification
  3. of prostate cancer. J. Urol., 1983, 129, 315. ? 2. Bhatti S., Shaw M., Guinan P.:
  4. Significance of prostate specific antigen. Proceedings Seventy ? Seventh Annual
  5. Meeting of the American Association for Cancer Research, 1986, 27, 365. ? 3. Chou
  6. T. M., Muphy G. P.: What's new in tumor markers for prostate cancer? Urology.
  7. 1986, 27, 487. ? 4. Devos P.G.M., Gerits M.J., Wellens A.M., De Roo M.J.K.: Com­
  8. parison of radioimmunoassays for prostate specific antigen. Nuc. Compact, 1987, 18,
  9. 235. ? 5. Kulpa J., Leńko J., Kwinta A , Wójcik E., Marczyńska A.: Kształtowanie
  10. się stężenia kwaśnej fosfatazy sterczowej w osoczu u chorych operowanych z po­
  11. wodu gruczolaka stercza. Urol. Pol., 1986, 39, 93. ? 6. Kuriyama M., Loor R., Wang
  12. M.C., Killian CS., Papsidero L.D., Inaji H., Nishiura T., Slack N.H., Murphy G.T.,
  13. Chu T. M.: Prostatic acid phosphatase and Prostate-specific antigen in prostate can­
  14. cer. Inter. Adv. Surg. Oncol.,1982, 5, 29. ? 7. Kuriyama M., Wang M.C, Papsidero
  15. L. D., Killian C. S., Shimano T., Valenzuela L. A, Nishiura T., Murphy G. P., Chu
  16. T. M.: Quantitation of Prostate-specific antigen in serum by sensitive enzyme im­
  17. munoassay. Cancer Res., 1980, 40, 4658. ? 8. Leńko J.: Rak stercza. Urol. Pol., 1984,
  18. 37, 245. ? 9. Leńko J., Marczyńska A., Kulpa J., Kwinta A,, Bugajski A.: Bioche­
  19. mical Control investigations (determinations of prostatic phosphatase ? carcino­
  20. embryonic antigen, alkaline phosphatase) in patients treated for prostatic carci­
  21. noma. Preliminary estimation effectiveness. Mat. Med. Pol., 1986, 4, 228. ?
  22. 10. .Marczyńska A., Kulpa J., Adamczyk B., Leńko J.: Kwaśna fosfataza su­
  23. rowicy krwi oznaczana metodą radioimmunochemiczną (PAP ? RIA); ocena war­
  24. tości diagnostycznej u chorych na raka stercza (doniesienie tymczasowe). Przeg.
  25. Lek., 1982, 39, 593.
  26. 11. Morote J., Ruibal A., Palou J.: Evaluation of specific antigen and pros­
  27. tatic phosphatase specificity. Study of false values. Int. J. Biolog. Markers, 1986, 1,
  28. 141. ? 12. Pontes J. D.: Biological markers in prostate cancer. A review. J. Urol.,
  29. 1983, 130, 1037. ? 13. Seamonds B., Yang N,, Anderson K., Whitaker B., Shaw L. M.,
  30. Bolliger J. R.: Evaluation of Prostate-specific antigen and prostatic acid phospha­
  31. tase as prostate cancer markers. Urology, 1986, 28. 472. ? 14. Stamey T. A., Yang N,,
  32. Hay A.R., McNeal J.E., Frehia F.S., Radwine E.: Prostate-specific antigen as se­
  33. rum marker for adenocarcinoma of the prostate New Eng. J. Med., 1987, 15, 317. ?
  34. 15. Wang M.C, Kuriyama M., Papsidero L.D., Loor R.M., Valenzuela L. A., Murphy
  35. G. P.,Chu T. M.: Prostate antigen of human cancer patients. Methods in Cancer
  36. Research, 1982, 19, 179. ? 16. Whitmore W.F.: The natural history of prostatic;
  37. cancer. Cancer, 1972, 32, 1104. ? 17. Woolf Ch. M.: Statistics for biologists. Princi­
  38. ples of biometry. B. Van Nostrand Comp. Inc, Toronto. London, Melbourne, 1968.